Report of Foreign Issuer (6-k)
November 15 2017 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2017
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
Level 5, 20 George Street, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☑ Form 40-F ☐
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note
: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note
:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☑
If
yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited
(Registrant)
Kate Hill
Kate Hill
Company Secretary
Date 15 November 2017
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd
(Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
483 M
Board of Directors
Mr Iain Ross
Chairman
Non-Executive Director
Mr Bryce Carmine
Non-Executive Director
Mr Steven Coffey
Non-Executive Director
Dr James Garner
Chief Executive Officer
Managing Director
|
|
MARKET RELEASE
15 November 2017
NOVOGEN AGM RESULTS
Sydney, 15 November 2017 Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an
Australian oncology drug development company, is delighted to announce its AGM results.
All resolutions were carried. Details are attached.
[ENDS]
About Novogen Limited
Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of
development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best- in-class agents in a range of oncology indications.
The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR
pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, TRX-E-002-01 (Cantrixil) commenced a phase I
clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.
For more information, please visit:
www.novogen.com
|
|
|
|
|
|
|
|
Novogen Limited
2017 Annual General Meeting
Wednesday, 15 November 2017
Voting Results
|
|
|
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resolution details
|
|
Instructions given to validly appointed proxies
(as at proxy close)
|
|
Number of votes cast on the poll
(where applicable)
|
|
Resolution
Result
|
Resolution
|
|
Resolution
Type
|
|
For
|
|
Against
|
|
Proxys
Discretion
|
|
Abstain
|
|
For
|
|
Against
|
|
Abstain*
|
|
Carried /
Not Carried
|
1 Adoption of Remuneration Report
|
|
Ordinary
|
|
87,127,527
75.30%
|
|
22,946,066
19.83%
|
|
5,634,860
4.87%
|
|
11,554,135
|
|
94,301,105
79.08%
|
|
24,946,066
20.92%
|
|
11,554,135
|
|
Carried
|
2 Re-election of Bryce Carmine
|
|
Ordinary
|
|
113,345,668
81.43%
|
|
20,196,984
14.51%
|
|
5,654,717
4.06%
|
|
2,132,846
|
|
120,864,138
84.48%
|
|
22,196,984
15.52%
|
|
2,132,846
|
|
Carried
|
3 Changing the name of the Company to Kazia Therapeutics Limited
|
|
Special
|
|
119,424,605
84.90%
|
|
15,587,115
11.09%
|
|
5,634,860
4.01%
|
|
683,635
|
|
128,923,218
89.21%
|
|
15,587,115
10.79%
|
|
683,635
|
|
Carried
|
4 Consolidation of the Companys shares
|
|
Special
|
|
107,518,659
78.50%
|
|
23,821,976
17.39%
|
|
5,634,860
4.11%
|
|
4,354,720
|
|
117,017,272
83.09%
|
|
23,821,976
16.91%
|
|
4,354,720
|
|
Carried
|
5 Approval of Employee Share Option Plan
|
|
Ordinary
|
|
98,134,942
73.34%
|
|
30,103,823
22.50%
|
|
5,565,610
4.16%
|
|
2,487,659
|
|
105,544,305
76.67%
|
|
32,123,823
23.33%
|
|
2,487,659
|
|
Carried
|
6 Approval of Increased Placement capacity under ASX Listing Rule 7.1A
|
|
Special
|
|
103,549,817
75.02%
|
|
28,852,121
20.90%
|
|
5,634,860
4.08%
|
|
3,293,417
|
|
111,048,430
78.26%
|
|
30,852,121
21.74%
|
|
3,293,417
|
|
Carried
|
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Sep 2023 to Sep 2024